Home -> Law Blog Directory -> Patent Law Blogs -> Patent Docs

Patent Law

: Patent Docs

Patent Profile: Hana Biosciences Receives Notice of Allowance for Use of Menadione to Treat EGFR Inhibitor-Associated Skin Rash

By Donald Zuhn, Kevin Noonan, Chris Singer, Sherri Oslick, and Jason Derry

By Nate Chongsiriwatana -- Hana Biosciences, Inc. recently announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Application No. 11/886,803, entitled "Vitamin K for Prevention and Treatment of Skin Rash Secondary to Anti-EGFR Therapy" (U.S. Patent Application Publication No. 2009/0209652 A1). Skin rash is a painful and common side effect of all approved epidermal growth factor receptor (EGFR) inhibitors (such as Tarceva®, Iressa®, Erbitux®, Vectibix®, and Tykerb®) that can limit treatment or make dose reduction necessary. As its title suggests, the '803 application discloses treatment of EGFR-associated skin rash with vitamin K3...

Full post as published by Patent Docs on May 11, 2010 (boomark / email).